Not a Member?
Email this page
Send the page ""
to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
Topical Dermatological AntifungalsTopical Scalp Antifungals
Topical preparation used to treat skin infections and eczema.
QUINJA Topical Gel: 1.25-1%
Apply to affected area(s) 3 to 4 times daily or as directed by a physician.
Maximum dosage information is not available.
>= 12 years: Maximum dosage information is not available.< 12 years: Safety and efficacy have not been established.
Safety and efficacy have not been established.
Specific guidelines for dosage adjustments in hepatic impairment are not available. Oral iodoquinol is contraindicated in patients with hepatic insufficiency; however, use of the topical preparation would not be expected to yield significant systemic concentrations. Use with caution.
Specific guidelines for dosage adjustments in renal impairment are not available; it appears that no dosage adjustments are needed.
Apply a thin film sparingly to the affected area.Do not cover with an occlusive dressing.Do not apply topical gel to eyes.
Aloquin:- Brief exposure up to 104 degrees F does not adversely affect product- Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees FQUINJA:- Store at 77 degrees F; brief exposure up to 104 degrees F does not adversely affect product- Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F
Aloe polysaccharide; iodoquinol is contraindicated in patients with known iodine hypersensitivity or iodoquinol hypersensitivity or a history of hypersensitivity reactions to any product components.
Aloe polysaccharide; iodoquinol should be used with caution in patients with thyroid disease (e.g., goiter, Graves' disease, hyperthyroidism or hypothyroidism). Iodoquinol contains 64% organically bound iodine. Significant systemic concentrations of iodine-containing drugs like iodoquinol may result in overt thyroid disease (e.g., iodine-induced hypothyroidism with associated goiter, or hyperthyroidism). It is unknown if topical iodoquinol preparations could result in thyroid disease; however, according to the manufacturer, iodoquinol may be absorbed through the skin and interfere with thyroid function tests.
Aloe polysaccharide; iodoquinol may produce a false positive ferric chloride test for phenylketonuria (PKU) if iodoquinol is present in the diaper or urine. Aloe polysaccharide; iodoquinol is not recommended for use in neonates, infants, or children < 12 years old and should not be used under a diaper or occlusive dressings.
Aloe polysaccharide; iodoquinol is classified as FDA pregnancy risk category C. No adequate and well-controlled studies have been conducted in pregnant women and its' ability to cause fetal harm or affect reproductive capacity is unknown. There have been limited case reports of oral iodoquinol used during pregnancy without apparent harm to the fetus. Iodoquinol contains 64% organically bound iodine, and the fetus is potentially susceptible to iodine-induced thyroid disorders or other potential iodoquinol side effects. It is unknown if topical use of iodoquinol could result in significant maternal or fetal concentrations. Administer during pregnancy only when clearly needed.
Data are limited regarding use of aloe polysaccharide; iodoquinol during breast-feeding and its' excretion in human breast milk is unknown. Elevated iodine concentrations in the breast-fed infant are theoretically possible, and neonates are among those persons susceptible to iodine-induced thyroid disorders. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally administered drug, health care providers are encouraged to report the adverse effect to the FDA.
pruritus / Rapid / Incidence not knownskin discoloration / Delayed / Incidence not knownurticaria / Rapid / Incidence not knownhair discoloration / Delayed / Incidence not knowndiarrhea / Early / Incidence not knownabdominal pain / Early / Incidence not knownvomiting / Early / Incidence not knownnausea / Early / Incidence not knownheadache / Early / Incidence not knownfever / Early / Incidence not knownvertigo / Early / Incidence not knownchills / Rapid / Incidence not known
There are no drug interactions associated with Aloe Polysaccharide; Iodoquinol products.
Mechanism of Action: The mechanism of activity of aloe polysaccharide; iodoquinol is unknown. Iodoquinol has antifungal and antibacterial activity.
Aloe polysaccharide; iodoquinol is administered topically. Pharmacokinetic data are not available.